Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Dose-Finding Study of LX1606 (Telotristat etiprate) in Symptomatic Carcinoid Syndrome
2009-016973-13Phase 2Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability of LX1606 and Symptomatic response. Started Dec 2009; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2009-016973-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016973-13.